Young Hwa Choi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Young Hwa Choi has a total of 323 co-authors. Here are the top co-authors by number of shared publications:
- Jun Yong Choi
Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
8 shared publications - Jung Yeon Heo
Department of Infectious Diseases, Ajou University School of Medicine, Suwon, Korea
8 shared publications Eun Jin Kim
Department of Infectious Diseases, Ajou University School of Medicine, Suwon, Korea
7 shared publications- Eun Jin Kim
Department of Infectious Diseases, Ajou University School of Medicine, Suwon, Korea
7 shared publications Hyeon Mi Yoo
Infection Control Office, Inje University Sanggye Paik Hospital, Seoul, Korea
5 shared publicationsMyoung Jin Shin
Department of Infectious Diseases, Ajou University School of Medicine, Suwon, South Korea
5 shared publications
Latest Publications
- Open Access
- 1 January 2027
- Published by XMLink in Journal of Korean Medical Science
- Vol. 42
Trends in Infectious Disease Burden in the Republic of Korea: Hospitalization, Mortality, and Case-Fatality, 2008–2019
Kim EJ, et al. J Korean Med Sci. 2027 Mar;42:e48. https://doi.org/10.3346/jkms.2027.42.e48
- 1 January 2027
- Published by XMLink in Journal of Korean Medical Science
- Vol. 42
Open AccessTrends in Infectious Disease Burden in the Republic of Korea: Hospitalization, Mortality, and Case-Fatality, 2008–2019
Kim EJ, et al. J Korean Med Sci. 2027 Mar;42:e48. https://doi.org/10.3346/jkms.2027.42.e48
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (38)
Trends and Causes of Hospitalization Among People With HIV in Korea: A 20-Year Observational Study
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (38)
Open AccessTrends and Causes of Hospitalization Among People With HIV in Korea: A 20-Year Observational Study
- Open Access
- 1 January 2025
- Published by XMLink in Yonsei Medical Journal
- Vol. 66 (9) , 609-617
Optimizing Vancomycin Area under the Concentration-Time Curve Targets in Enterococcal Bacteremia: Balancing Efficacy and Nephrotoxicity
Kim YR, et al. Yonsei Med J. 2025 Jun;66:e63. https://doi.org/10.3349/ymj.2024.0513
- 1 January 2025
- Published by XMLink in Yonsei Medical Journal
- Vol. 66 (9) , 609-617
Open AccessOptimizing Vancomycin Area under the Concentration-Time Curve Targets in Enterococcal Bacteremia: Balancing Efficacy and Nephrotoxicity
Kim YR, et al. Yonsei Med J. 2025 Jun;66:e63. https://doi.org/10.3349/ymj.2024.0513
- Open Access
- 2 September 2024
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 24 (1) , 1-8
Clinical outcome of ampicillin or ampicillin/sulbactam versus glycopeptides in ampicillin-susceptible Enterococcus faecalis/faecium bacteremia: a 10-year retrospective cohort study
Background: Glycopeptides for ampicillin-susceptible Enterococcus faecalis/faecium bacteremia are readily prescribed depending on the severity of the condition. However, there is limited data on the outcomes of glycopeptide use compared to ampicillin-containing regimens for ampicillin-susceptible E. faecalis/faecium bacteremia. From an antibiotic stewardship perspective, it is important to determine whether the use of glycopeptides is associated with improved clinical outcomes in patients with ampicillin-susceptible E. faecalis/faecium bacteremia. Methods: This retrospective cohort study was conducted at a university-affiliated hospital between January 2010 and September 2019. We collected data from patients with positive blood cultures for Enterococcus species isolates. The clinical data of patients who received ampicillin-containing regimens or glycopeptides as definitive therapy for ampicillin-susceptible E. faecalis/faecium bacteremia were reviewed. Multivariate logistic regression analysis was performed to identify risk factors for 28-day mortality. Results: Ampicillin-susceptible E. faecalis/faecium accounted for 41.2% (557/1,353) of enterococcal bacteremia cases during the study period. A total of 127 patients who received ampicillin-containing regimens (N = 56) or glycopeptides (N = 71) as definitive therapy were included in the analysis. The 28-day mortality rate was higher in patients treated with glycopeptides (19.7%) than in those treated with ampicillin-containing regimens (3.6%) (p = 0.006). However, in the multivariate model, antibiotic choice was not an independent predictor of 28-day mortality (adjusted OR, 3.7; 95% CI, 0.6–23.6). Conclusions: Glycopeptide use was not associated with improved mortality in patients with ampicillin-susceptible E. faecalis/faecium bacteremia. This study provides insights to reduce the inappropriate use of glycopeptides in ampicillin-susceptible E. faecalis/faecium bacteremia treatment and promote antimicrobial stewardship.
- 2 September 2024
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 24 (1) , 1-8
Open AccessClinical outcome of ampicillin or ampicillin/sulbactam versus glycopeptides in ampicillin-susceptible Enterococcus faecalis/faecium bacteremia: a 10-year retrospective cohort study
Background: Glycopeptides for ampicillin-susceptible Enterococcus faecalis/faecium bacteremia are readily prescribed depending on the severity of the condition. However, there is limited data on the outcomes of glycopeptide use compared to ampicillin-containing regimens for ampicillin-susceptible E. faecalis/faecium bacteremia. From an antibiotic stewardship perspective, it is important to determine whether the use of glycopeptides is associated with improved clinical outcomes in patients with ampicillin-susceptible E. faecalis/faecium bacteremia. Methods: This retrospective cohort study was conducted at a university-affiliated hospital between January 2010 and September 2019. We collected data from patients with positive blood cultures for Enterococcus species isolates. The clinical data of patients who received ampicillin-containing regimens or glycopeptides as definitive therapy for ampicillin-susceptible E. faecalis/faecium bacteremia were reviewed. Multivariate logistic regression analysis was performed to identify risk factors for 28-day mortality. Results: Ampicillin-susceptible E. faecalis/faecium accounted for 41.2% (557/1,353) of enterococcal bacteremia cases during the study period. A total of 127 patients who received ampicillin-containing regimens (N = 56) or glycopeptides (N = 71) as definitive therapy were included in the analysis. The 28-day mortality rate was higher in patients treated with glycopeptides (19.7%) than in those treated with ampicillin-containing regimens (3.6%) (p = 0.006). However, in the multivariate model, antibiotic choice was not an independent predictor of 28-day mortality (adjusted OR, 3.7; 95% CI, 0.6–23.6). Conclusions: Glycopeptide use was not associated with improved mortality in patients with ampicillin-susceptible E. faecalis/faecium bacteremia. This study provides insights to reduce the inappropriate use of glycopeptides in ampicillin-susceptible E. faecalis/faecium bacteremia treatment and promote antimicrobial stewardship.
- Open Access
- 30 June 2024
- Published by Korean Society for Healthcare-associated Infection Control and Prevention in Korean Journal of Healthcare-Associated Infection Control and Prevention
- Vol. 29 (1) , 27-39
Waterborne Healthcare Outbreaks and Its Prevention Strategies
Young Rong Kim, Young Hwa Choi. Korean J healthc assoc Infect Control Prev 2024;29:27-39. https://doi.org/10.14192/kjicp.2024.29.1.27
- 30 June 2024
- Published by Korean Society for Healthcare-associated Infection Control and Prevention in Korean Journal of Healthcare-Associated Infection Control and Prevention
- Vol. 29 (1) , 27-39
Open AccessWaterborne Healthcare Outbreaks and Its Prevention Strategies
Young Rong Kim, Young Hwa Choi. Korean J healthc assoc Infect Control Prev 2024;29:27-39. https://doi.org/10.14192/kjicp.2024.29.1.27
- Open Access
- 10 March 2024
- Published by Korean Medical Association in Journal of the Korean Medical Association
- Vol. 67 (3) , 148-152
The current state and outlook of HIV infection and AIDS in South Korea
Background: Over the past decade, approximately 1,100 newly diagnosed cases of human immunodeficiency virus (HIV) infection have been reported annually in South Korea, with 1,066 newly diagnosed cases reported in 2022. A decrease in HIV infection rate can be achieved only through coordinated prevention, diagnosis, and treatment. South Korea is lagging in the worldwide decreasing trend of HIV infection, and a brief review of this situation may suggest improvements necessary for progress.Current Concepts: In South Korea, the proportion of patients with CD4 cell count below 200 cells/mm3 at initial diagnosis of HIV infection remains high, suggesting that a significant population is diagnosed at the late stage of the disease. Since 2019, the Korean National Health Insurance Service began to cover the cost of preexposure prophylaxis for sexual partners of patients living with HIV, but few have started the regimen due to several barriers. Insurance criteria for a prophylaxis regimen should be modified, and accessibility to the regimen should be made available through multiple pathways. Proactive use of rapid HIV testing kits in community health centers and clinics should be expanded. Legal and administrative environments encouraging voluntary testing, early diagnosis, and treatment should be fostered. Medical personnel must be able to offer medical care without discrimination regardless of HIV infection status.Discussion and Conclusion: The HIV epidemic in South Korea has not yet decreased. To end it, efforts should be required across broad areas, including voluntary HIV testing, early diagnosis, active pre-exposure prophylaxis, a stigma- and discrimination-free social environment, and changes in legal and medical environments.
- 10 March 2024
- Published by Korean Medical Association in Journal of the Korean Medical Association
- Vol. 67 (3) , 148-152
Open AccessThe current state and outlook of HIV infection and AIDS in South Korea
Background: Over the past decade, approximately 1,100 newly diagnosed cases of human immunodeficiency virus (HIV) infection have been reported annually in South Korea, with 1,066 newly diagnosed cases reported in 2022. A decrease in HIV infection rate can be achieved only through coordinated prevention, diagnosis, and treatment. South Korea is lagging in the worldwide decreasing trend of HIV infection, and a brief review of this situation may suggest improvements necessary for progress.Current Concepts: In South Korea, the proportion of patients with CD4 cell count below 200 cells/mm3 at initial diagnosis of HIV infection remains high, suggesting that a significant population is diagnosed at the late stage of the disease. Since 2019, the Korean National Health Insurance Service began to cover the cost of preexposure prophylaxis for sexual partners of patients living with HIV, but few have started the regimen due to several barriers. Insurance criteria for a prophylaxis regimen should be modified, and accessibility to the regimen should be made available through multiple pathways. Proactive use of rapid HIV testing kits in community health centers and clinics should be expanded. Legal and administrative environments encouraging voluntary testing, early diagnosis, and treatment should be fostered. Medical personnel must be able to offer medical care without discrimination regardless of HIV infection status.Discussion and Conclusion: The HIV epidemic in South Korea has not yet decreased. To end it, efforts should be required across broad areas, including voluntary HIV testing, early diagnosis, active pre-exposure prophylaxis, a stigma- and discrimination-free social environment, and changes in legal and medical environments.
- Open Access
- 1 January 2024
- Published by XMLink in Infection & Chemotherapy
- Vol. 56 (3) , 369-377
Epidemiological and Clinical Characteristics of Women Living with HIV in Korea
Ahn SM, et al. Infect Chemother. 2024 Sep;56:e42. https://doi.org/10.3947/ic.2024.0057
- 1 January 2024
- Published by XMLink in Infection & Chemotherapy
- Vol. 56 (3) , 369-377
Open AccessEpidemiological and Clinical Characteristics of Women Living with HIV in Korea
Ahn SM, et al. Infect Chemother. 2024 Sep;56:e42. https://doi.org/10.3947/ic.2024.0057
- Open Access
- 1 January 2024
- Published by XMLink in Infection & Chemotherapy
- Vol. 56 (2) , 188-203
Recommendations for Adult Immunization by the Korean Society of Infectious Diseases, 2023: Minor Revisions to the 3rd Edition
Choi WS, et al. Infect Chemother. 2024 Jun;56:e28. https://doi.org/10.3947/ic.2023.0072
- 1 January 2024
- Published by XMLink in Infection & Chemotherapy
- Vol. 56 (2) , 188-203
Open AccessRecommendations for Adult Immunization by the Korean Society of Infectious Diseases, 2023: Minor Revisions to the 3rd Edition
Choi WS, et al. Infect Chemother. 2024 Jun;56:e28. https://doi.org/10.3947/ic.2023.0072
- Open Access
- 31 December 2023
- Published by Korean Society for Healthcare-associated Infection Control and Prevention in Korean Journal of Healthcare-Associated Infection Control and Prevention
- Vol. 28 (2) , 240-242
A Glance at History of Infection Control Guide; from Guidebook to Textbook
Young Hwa Choi. Korean J healthc assoc Infect Control Prev 2023;28:240-2. https://doi.org/10.14192/kjicp.2023.28.2.240
- 31 December 2023
- Published by Korean Society for Healthcare-associated Infection Control and Prevention in Korean Journal of Healthcare-Associated Infection Control and Prevention
- Vol. 28 (2) , 240-242
Open AccessA Glance at History of Infection Control Guide; from Guidebook to Textbook
Young Hwa Choi. Korean J healthc assoc Infect Control Prev 2023;28:240-2. https://doi.org/10.14192/kjicp.2023.28.2.240
- Open Access
- 5 August 2023
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 16 (10) , 1643-1649
The third dose of measles-containing vaccine induces robust immune responses against measles in young seronegative healthcare workers who had previous two-dose measles vaccination
- 5 August 2023
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 16 (10) , 1643-1649
Open AccessThe third dose of measles-containing vaccine induces robust immune responses against measles in young seronegative healthcare workers who had previous two-dose measles vaccination